Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Carlyle Group's $3.8B Bid For NBTY Could Face Competition

This article was originally published in The Tan Sheet

Executive Summary

The Carlyle Group's planned acquisition of NBTY for $3.8 billion may not be the only private equity offer to surface for the dietary supplement giant

You may also be interested in...



NBTY Acquires Balance Bar To Expand In Sports Category

The acquisition from private equity firm Brynwood Partners includes four product lines under the Balance Bar brand, which NBTY claims is one of the most recognizable in the nutrition bar category, a growing sector where the firm already has a sizable presence.

NBTY Acquires Balance Bar To Expand In Sports Category

The acquisition from private equity firm Brynwood Partners includes four product lines under the Balance Bar brand, which NBTY claims is one of the most recognizable in the nutrition bar category, a growing sector where the firm already has a sizable presence.

DSM's $1.1B Martek Acquisition Comes With Potential IP Expirations

Dutch ingredients giant Royal DSM N.V. incurs no incremental risk in acquiring Martek Biosciences despite the looming expiration dates for Martek's intellectual property, according to a market analyst.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel